Related Experiment Videos
[Initial experience with the use of mitomycin C in anti-glaucoma filtering surgery]
1Ocní klinika Fakultní nemocnice, Hradec Králové.
Abstract:
The authors report on their initial experience with the use of peroperative administration of mitomycin C (0.5 mg/ml for a period of 5 mins.) in complicated cases of glaucoma. In 14 eyes of 15 with a mean observation period of 8 months compensation of the intraocular pressure was achieved. In one eye 5 months after a filtering operation transplantation of the cornea was performed with secondary implantation of the posterior-chamber intraocular lens, decompensation of the intraocular pressure was treated 11 months after the filtering operation by cyclocryotherapy. Mitomycin C is a promising substance which improves substantially the prognosis of complicated cases of glaucoma.
Insights
Mitomycin C improved intraocular pressure control in complicated glaucoma cases. This antimetabolite agent offers a promising outlook for managing challenging glaucoma patients.
Area of Science:
- Ophthalmology
- Pharmacology
Context:
- Complicated glaucoma cases present significant treatment challenges.
- Standard surgical interventions may have limited success in advanced glaucoma.
Purpose:
- To evaluate the efficacy of intraoperative mitomycin C in managing complicated glaucoma.
- To assess the safety and outcomes of this adjunctive therapy.
Summary:
- Mitomycin C (0.5 mg/ml for 5 minutes) was administered during surgery in 15 eyes with complicated glaucoma.
- Successful intraocular pressure control was achieved in 14 eyes over an 8-month follow-up.
- One eye required corneal transplantation and lens implantation; another needed cyclocryotherapy for persistent pressure elevation.
Impact:
- Intraoperative mitomycin C demonstrates potential to improve surgical outcomes in complicated glaucoma.
- This approach may enhance the long-term prognosis for patients with severe forms of glaucoma.